PI3K-gamma inhibitor IPI-549
GPTKB entity
Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
small molecule
investigational drug |
| gptkbp:alternativeName |
gptkb:IPI-549
Eganelisib |
| gptkbp:CASNumber |
1693758-51-8
|
| gptkbp:chemicalFormula |
C24H24N6O2
|
| gptkbp:clinicalTrialPhase |
solid tumors
advanced cancers Phase 1/1b |
| gptkbp:combinationTherapy |
immune checkpoint inhibitors
|
| gptkbp:developedBy |
gptkb:Infinity_Pharmaceuticals
|
| gptkbp:effect |
reduces immunosuppression
modulates tumor immune microenvironment |
| gptkbp:firstReported |
2016
|
| https://www.w3.org/2000/01/rdf-schema#label |
PI3K-gamma inhibitor IPI-549
|
| gptkbp:intendedUse |
immunotherapy
|
| gptkbp:mechanismOfAction |
inhibits PI3K-gamma enzyme
|
| gptkbp:molecularWeight |
428.49 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
gptkb:PI3K-gamma
|
| gptkbp:bfsParent |
gptkb:IPI-549
|
| gptkbp:bfsLayer |
6
|